• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

ViaCyte

embryonic stem cells
Biotech

Vertex buys ViaCyte for $320M, clearing out T1D competition

Vertex is absorbing ViaCyte for $320 million, taking a bulldozer to the competition of another stem cell-based treatment for diabetes.
Max Bayer Jul 11, 2022 11:45am
Parachute

AltruBio snags new CMO with pivot to immunology—Chutes & Ladders

Sep 17, 2021 9:30am
diabetes strip blood glucose monitor

ViaCyte staffs up CSO role to drive diabetes treatments

Sep 13, 2021 1:00pm
20 dollar bills

ViaCyte scores $45M for type 1 diabetes drugs in midstage trials

Jun 9, 2021 2:47pm
ViaCyte CEO Paul Laikind

ViaCyte bags $80M to trial diabetes stem cell therapies

Nov 29, 2018 8:11am
DNA

CRISPR, ViaCyte team up on gene-edited diabetes treatment

Sep 17, 2018 11:12am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy